Autotac is an innovative Korean startup specializing in protein target decomposition drugs. Their cutting-edge technology focuses on developing therapeutics for a range of diseases, including cancers, degenerative brain diseases, amyloid diseases, autoimmunity, and viral infections such as coronavirus.

Autotac’s vision is to pioneer new treatments for rare and incurable diseases, improving patient health globally. Our mission is to harness autophagy-based target decomposition technology to create effective and novel therapeutics.

Noteworthy Points:

• Founded in 2015 and headquartered in Seoul, South Korea.
• Raised $16.4M in Series B funding as of March 2022.
• Holds patents for neurodegenerative disease treatments through autophagy activity.